Table 3

Physician behaviour and motivations for continuous or intermittent ADT among patients with non-metastatic prostate cancer

Behaviour and GnRH reason for useNumber of physicians (%)Continuous ADT ≥6 months (%)Intermittent ADT (%)
PSA testing frequency (n=441)
 ≥1/month2 (0.5)  40.7  59.3
 Every 1–3 months151 (34.2)66.627.5
 Every 4–6 months  208 (47.1)63.432.3
 Every 7–12 months72 (16.3)63.131.2
 <1/year8 (1.8)67.927.9
PSA level used for decision to initiate GnRH (n=441)
 Yes282 (63.9)64.630.2
 No159 (36.1)63.931.4
PSA level, yes (n=282)
 0–953 (18.8)64.829.0
 10–20172 (61.0)64.531.5
 >2057 (20.2)64.827.2
PSA doubling time used for decision to initiate GnRH (n=441)
 Yes254 (57.6)63.231.2
 No187 (42.4)66.129.8
PSA doubling time, yes (n=254) (months)
 0–374 (29.1)67.229.1
 >3–6123 (48.3)60.134.1
 >6–1252 (20.5)62.529.3
 >125 (2.0)85.511.1
Gleason score used for decision to initiate GnRH (n=441)
 Yes290 (65.8)65.730.2
 No151 (34.2)62.431.6
Gleason score, yes (n=290)
 3–57 (2.4)65.125.1
 620 (6.9)66.430.6
 7–8250 (86.2)65.231.1
 9–1013 (4.5)73.416.9
Testosterone testing frequency
 ≤3 months43 (9.8)62.730.9
 4–6 months61 (13.8)67.529.2
 7–12+ months36 (8.2)54.740.4
 <1 per year44 (10.0)62.434.4
 Do not test257 (58.3)65.728.8
  • ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; PSA, prostate-specific antigen.